T. Rowe Price Associates
HCAT icon

T. Rowe Price Associates’s Health Catalyst HCAT Stock Holding History

T. Rowe Price Associates’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Sell
67,863
-31,347
-32% -$45.3K ﹤0.01% 3100
2026
Q1 		$126K Buy
99,210
+11,782
+13% +$22.2K ﹤0.01% 2945
2025
Q4 		$209K Buy
87,428
+5,100
+6% +$13.9K ﹤0.01% 2792
2025
Q3 		$235K Hold
82,328
– – ﹤0.01% 2725
2025
Q2 		$311K Buy
82,328
+7,122
+9% +$28K ﹤0.01% 2512
2025
Q1 		$341K Buy
75,206
+12,763
+20% +$67.5K ﹤0.01% 2411
2024
Q4 		$442K Buy
62,443
+4,798
+8% +$38.2K ﹤0.01% 2335
2024
Q3 		$470K Buy
57,645
+557
+1% +$4.03K ﹤0.01% 2271
2024
Q2 		$365K Buy
57,088
+7,342
+15% +$47.1K ﹤0.01% 2320
2024
Q1 		$375K Buy
49,746
+2,831
+6% +$25.8K ﹤0.01% 2327
2023
Q4 		$435K Buy
46,915
+4,941
+12% +$40.4K ﹤0.01% 2235
2023
Q3 		$425K Buy
41,974
+1,541
+4% +$18.4K ﹤0.01% 2193
2023
Q2 		$506K Buy
40,433
+676
+2% +$8.05K ﹤0.01% 2123
2023
Q1 		$464K Buy
39,757
+970
+3% +$12.4K ﹤0.01% 2147
2022
Q4 		$412K Buy
38,787
+3,613
+10% +$34.9K ﹤0.01% 2224
2022
Q3 		$342K Buy
35,174
+8,887
+34% +$118K ﹤0.01% 2318
2022
Q2 		$381K Buy
26,287
+5,804
+28% +$99K ﹤0.01% 2335
2022
Q1 		$535K Buy
20,483
+5,142
+34% +$146K ﹤0.01% 2305
2021
Q4 		$608K Sell
15,341
-664
-4% -$30.3K ﹤0.01% 2300
2021
Q3 		$800K Buy
16,005
+491
+3% +$26.8K ﹤0.01% 2153
2021
Q2 		$861K Buy
15,514
+1,431
+10% +$76.2K ﹤0.01% 2134
2021
Q1 		$659K Buy
14,083
+13
+0.1% +$630 ﹤0.01% 2235
2020
Q4 		$612K Sell
14,070
-170,213
-92% -$6.28M ﹤0.01% 2164
2020
Q3 		$6.75M Sell
184,283
-156,607
-46% -$5.32M ﹤0.01% 1366
2020
Q2 		$9.94M Sell
340,890
-134,384
-28% -$3.71M ﹤0.01% 1298
2020
Q1 		$12.4M Buy
475,274
+194,037
+69% +$5.93M ﹤0.01% 1191
2019
Q4 		$9.76M Sell
281,237
-19,499
-6% -$645K ﹤0.01% 1316
2019
Q3 		$9.52M Buy
+300,736
New +$11.8M ﹤0.01% 1302

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's HCAT Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Health Catalyst (HCAT) stake by 32% in Q2 2026, selling an estimated $45.3K and leaving 67,863 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #3100.

T. Rowe Price Associates first reported a position in HCAT in Q3 2019 and has held it in 28 quarters since. The position peaked at $12.4M in Q1 2020. 127 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • T. Rowe Price Associates held 67,863 shares of Health Catalyst worth $136K as of Q2 2026.
  • T. Rowe Price Associates sold 31,347 Health Catalyst shares in Q2 2026, an estimated $45.3K.
  • Health Catalyst made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3100 holding.
  • T. Rowe Price Associates first reported a position in Health Catalyst in Q3 2019 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Health Catalyst position peaked at $12.4M in Q1 2020.
  • 127 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.